These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 2803458)

  • 1. The minimum inhibitory concentrations of various bismuth salts against Campylobacter pylori.
    Vogt K; Warrelmann M; Hahn H
    Zentralbl Bakteriol; 1989 Sep; 271(3):304-10. PubMed ID: 2803458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of bismuth subcarbonate against Campylobacter pylori: do citrate ions improve antibacterial activity?
    Vogt K; Warrelmann M; Hahn H
    Zentralbl Bakteriol; 1990 May; 273(1):33-5. PubMed ID: 2363796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastric anti-secretory, mucosal protective, anti-pepsin and anti-Helicobacter properties of ranitidine bismuth citrate.
    Stables R; Campbell CJ; Clayton NM; Clitherow JW; Grinham CJ; McColm AA; McLaren A; Trevethick MA
    Aliment Pharmacol Ther; 1993 Jun; 7(3):237-46. PubMed ID: 8364129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro susceptibility of Campylobacter pyloridis to cimetidine, sucralfate, bismuth and sixteen antibiotics.
    Andreasen JJ; Andersen LP
    Acta Pathol Microbiol Immunol Scand B; 1987 Apr; 95(2):147-9. PubMed ID: 3591312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentiation of the action of metronidazole on Helicobacter pylori by omeprazole and bismuth subcitrate.
    Andersen LP; Colding H; Kristiansen JE
    Int J Antimicrob Agents; 2000 Apr; 14(3):231-4. PubMed ID: 10773493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo susceptibility of Campylobacter pylori.
    Graham DY; Klein PD; Opekun AR; Smith KE; Polasani RR; Evans DJ; Evans DG; Alpert LC; Michaletz PA; Yoshimura HH
    Am J Gastroenterol; 1989 Mar; 84(3):233-8. PubMed ID: 2919580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutics used to alleviate peptic ulcers inhibit H. pylori receptor binding in vitro.
    Huesca M; Gold B; Sherman P; Lewin P; Lingwood C
    Zentralbl Bakteriol; 1993 Sep; 280(1-2):244-52. PubMed ID: 8280948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacology of bismuth-containing compounds.
    Lambert JR
    Rev Infect Dis; 1991; 13 Suppl 8():S691-5. PubMed ID: 1925310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of tripotassium dicitrato bismuthate on the rat stomach.
    Waldum HL; Qvigstad G; Mårvik R; Brenna E; Syversen U; Sandvik AK
    Aliment Pharmacol Ther; 1994 Aug; 8(4):425-31. PubMed ID: 7527257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Solubility, absorption, and anti-Helicobacter pylori activity of bismuth subnitrate and colloidal bismuth subcitrate: In vitro data Do not predict In vivo efficacy.
    Phillips RH; Whitehead MW; Lacey S; Champion M; Thompson RP; Powell JJ
    Helicobacter; 2000 Sep; 5(3):176-82. PubMed ID: 10971684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro synergistic activity between bismuth subcitrate and various antimicrobial agents against Campylobacter pyloridis (C. pylori).
    Van Caekenberghe DL; Breyssens J
    Antimicrob Agents Chemother; 1987 Sep; 31(9):1429-30. PubMed ID: 3674850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined activity of trospectomycin and colloidal bismuth subcitrate against Helicobacter pylori in vitro.
    Vogt K; Rodloff AC; Hahn H
    Infection; 1991; 19(3):138-9. PubMed ID: 1832417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitivity of Campylobacter pylori to colloidal bismuth subcitrate.
    Goodwin CS; Bell B; McCullough C; Turner M
    J Clin Pathol; 1989 Feb; 42(2):216-7. PubMed ID: 2921366
    [No Abstract]   [Full Text] [Related]  

  • 14. Bismuth accumulates in the body during treatment with tripotassium dicitrato bismuthate.
    Gavey CJ; Szeto ML; Nwokolo CU; Sercombe J; Pounder RE
    Aliment Pharmacol Ther; 1989 Feb; 3(1):21-8. PubMed ID: 2491455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of bismuth and nitecapone on acetaldehyde production by Helicobacter pylori.
    Salmela KS; Roine RP; Höök-Nikanne J; Kosunen TU; Salaspuro M
    Scand J Gastroenterol; 1994 Jun; 29(6):528-31. PubMed ID: 8079111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omeprazole-induced increase in the absorption of bismuth from tripotassium dicitrato bismuthate.
    Treiber G; Walker S; Klotz U
    Clin Pharmacol Ther; 1994 May; 55(5):486-91. PubMed ID: 8181192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo effects of three bismuth compounds on fermentation by colonic bacteria.
    León-Barúa R; Tello R; Morante MC; Alvarez M; Gilman RH; Spira WM
    Rev Infect Dis; 1990; 12 Suppl 1():S24-9. PubMed ID: 2305175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergism between clindamycin and colloidal bismuth subcitrate against Helicobacter (Campylobacter) pylori in vitro.
    Vogt K; Hahn H
    Zentralbl Bakteriol; 1990 Nov; 274(2):246-9. PubMed ID: 2085373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective coating of gastric ulcer by tripotassium dicitrato bismuthate in the rat.
    Koo J; Ho J; Lam SK; Wong J; Ong GB
    Gastroenterology; 1982 May; 82(5 Pt 1):864-70. PubMed ID: 7060908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of in vitro antibiotic resistance on treatment: bismuth-containing regimens.
    Chiba N
    Can J Gastroenterol; 2000 Nov; 14(10):885-9. PubMed ID: 11111112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.